Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Upgraded by Zacks Research

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

PTHS has been the subject of a number of other research reports. Oppenheimer upped their target price on shares of Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, March 20th. Piper Sandler began coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price objective for the company. Roth Mkm reduced their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.25.

Pelthos Therapeutics Price Performance

PTHS stock opened at $22.09 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 2.05 and a debt-to-equity ratio of 0.81. Pelthos Therapeutics has a 1-year low of $9.00 and a 1-year high of $54.29. The business has a 50 day simple moving average of $23.21. The company has a market cap of $74.22 million, a P/E ratio of -1.06 and a beta of 3.87.

Institutional Trading of Pelthos Therapeutics

Hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC lifted its holdings in shares of Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares during the last quarter. Boothbay Fund Management LLC increased its stake in Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. J. Goldman & Co LP purchased a new stake in Pelthos Therapeutics during the fourth quarter valued at approximately $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in Pelthos Therapeutics during the fourth quarter valued at approximately $1,085,000. Finally, Diadema Partners LP lifted its stake in shares of Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after purchasing an additional 14,502 shares during the last quarter. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).